Trulicity vs Retatrutide: Real-World Evidence Comparison

What Are These Two Drugs and How Do They Differ Mechanistically?

Dulaglutide (Trulicity) activates only the GLP-1 receptor, slowing gastric emptying, stimulating glucose-dependent insulin secretion, and reducing appetite through central nervous system pathways. Retatrutide hits three receptors simultaneously: GIP, GLP-1, and glucagon. That third target, the glucagon receptor, adds thermogenic and lipolytic activity not seen with single or dual agonists, which is the main reason its weight loss numbers look so different from established GLP-1 drugs.

GLP-1 Single Agonism: What Dulaglutide Does

Dulaglutide binds selectively to the GLP-1 receptor with a half-life of approximately 5 days, which supports its once-weekly 0.75 mg or 1.5 mg (and up to 4.5 mg in the AWARD-11 dose-escalation trial) schedule. Its glucose-lowering mechanism depends on circulating glucose levels, which largely explains its low intrinsic hypoglycemia risk as monotherapy. The FDA approved it in September 2014 for glycemic control in adults with type 2 diabetes, and a subsequent cardiovascular indication followed the REWIND results.

Triple Agonism: The Retatrutide Mechanism

Retatrutide (LY3437943, developed by Eli Lilly) co-activates GIP, GLP-1, and glucagon receptors. Glucagon receptor co-agonism increases resting energy expenditure and accelerates hepatic fat oxidation. GIP receptor activation appears to amplify insulin secretion and may reduce GLP-1-associated nausea, based on mechanistic studies of the related dual agonist tirzepatide. The net effect in the Jastreboff et al. Phase 2 trial (N=338) was weight loss that exceeded every prior published trial for a pharmacological obesity intervention at the time of publication. Jastreboff AM, et al. NEJM 2023

Clinical Trial Efficacy: Weight Loss Head-to-Head

No randomized head-to-head trial comparing dulaglutide directly to retatrutide has been published. Comparing across separate trials is imperfect because patient populations, baseline BMI, background therapy, and trial duration all differ. With that caveat clearly stated, the magnitude gap between the two drugs is large enough to be clinically meaningful.

Dulaglutide Weight Loss Data

The AWARD-11 trial enrolled 1,842 adults with type 2 diabetes and tested dulaglutide 3.0 mg and 4.5 mg against the approved 1.5 mg dose. At 52 weeks, the 4.5 mg arm produced a mean HbA1c reduction of 1.87 percentage points and mean body weight loss of 6.0 kg (approximately 5.7 percent for a typical 105 kg patient). These numbers reflect a patient population with type 2 diabetes, not obesity alone, which matters for interpretation.

In people without diabetes, dulaglutide's weight effect is modest. A 2021 pooled analysis estimated 2 to 4 percent mean body weight reduction at approved doses in non-diabetic individuals, which sits below the thresholds most clinicians consider meaningful for obesity pharmacotherapy (typically 5 percent or greater).

Retatrutide Weight Loss Data

The Phase 2 dose-escalation trial published by Jastreboff et al. In the New England Journal of Medicine randomized 338 adults with obesity (BMI 30 or above, no diabetes) to retatrutide 1 mg, 4 mg, 8 mg, or 12 mg once weekly, or placebo, for 48 weeks. The 12 mg cohort achieved 24.2 percent mean weight loss. The 8 mg cohort achieved 19.65 percent. Even the 4 mg cohort reached 8.67 percent, comparable to approved doses of liraglutide. Jastreboff AM, et al. NEJM 2023

A practical decision framework for clinicians evaluating these two agents:

Step 1. Confirm the primary treatment goal. Cardiovascular risk reduction in type 2 diabetes? Dulaglutide has a dedicated CVOT (REWIND). Weight loss exceeding 15 percent in obesity? Retatrutide, once approved, is the better-evidenced option.

Step 2. Check approval and access. As of mid-2025, retatrutide remains investigational. Patients outside clinical trials cannot access it commercially.

Step 3. Assess GI tolerability history. Both agents carry a class-wide nausea risk. If a patient discontinued a prior GLP-1 due to severe nausea, the incremental GIP component of retatrutide may (based on tirzepatide data) reduce that burden, but this is not yet confirmed specifically for retatrutide.

Step 4. Consider hepatic steatosis. Retatrutide's glucagon receptor activity drives hepatic fat reduction beyond what GLP-1 monotherapy achieves. Patients with concurrent metabolic dysfunction-associated steatohepatitis may derive additional benefit.

Cardiovascular Outcomes: Where Dulaglutide Has a Clear Edge

Dulaglutide is one of a small number of glucose-lowering drugs with a positive dedicated cardiovascular outcomes trial. The REWIND trial enrolled 9,901 adults with type 2 diabetes, roughly half of whom had no prior cardiovascular event, making REWIND the largest primary-prevention CVOT in the GLP-1 class at the time of publication. Over a median follow-up of 5.4 years, dulaglutide reduced the composite of nonfatal MI, nonfatal stroke, and cardiovascular death by 12 percent relative to placebo (HR 0.88, 95% CI 0.79 to 0.99, P<0.026). Gerstein HC, et al. Lancet 2019

The REWIND investigators noted: "Dulaglutide could be considered for the management of glycaemia in middle-aged and older people with type 2 diabetes who have either established CVD or CVD risk factors." That quote reflects the FDA label update granting dulaglutide a cardiovascular risk-reduction indication in 2020.

Retatrutide has no published cardiovascular outcomes data. Phase 3 trials are ongoing and will likely include cardiovascular safety assessments, but a full CVOT takes years. Clinicians who select a GLP-1 agent specifically for MACE reduction in a high-risk patient with type 2 diabetes have no equivalent evidence for retatrutide yet.

Stroke Reduction Signal in REWIND

A secondary analysis of REWIND found that dulaglutide reduced nonfatal stroke by 24 percent (HR 0.76, 95% CI 0.61 to 0.95), a result that drove much of the overall composite benefit. This stroke signal has practical relevance for patients with atrial fibrillation, prior TIA, or hypertension-driven cerebrovascular risk.

Blood Pressure Effects

Both agents appear to lower systolic blood pressure modestly. REWIND participants on dulaglutide had a mean systolic BP reduction of approximately 1.7 mmHg versus placebo at 1 year, a small but directionally consistent finding. Retatrutide's glucagon agonism raises a theoretical concern about mild heart rate increases (also seen with GLP-1 monotherapy), though the Phase 2 data did not reveal unexpected cardiac safety signals in the 48-week observation window.

Glycemic Control in Type 2 Diabetes

Dulaglutide is primarily a diabetes drug. Its HbA1c reduction of 1.3 to 1.87 percentage points across the AWARD program, combined with a once-weekly injection and autoinjector pen design that requires no reconstitution, placed it among the most prescribed GLP-1 drugs globally before the rise of semaglutide and tirzepatide.

Retatrutide was studied in both diabetic and non-diabetic populations in Phase 2. A separate arm of the Jastreboff Phase 2 program in adults with type 2 diabetes showed HbA1c reductions ranging from 1.8 to 2.3 percentage points at the 12 mg dose. These numbers are competitive with dulaglutide's highest dose and approach the glycemic efficacy of tirzepatide, the approved dual GIP/GLP-1 agonist.

AWARD Program: Establishing Dulaglutide's Glycemic Profile

The AWARD (Assessment of Weekly Administration of LY2189265 in Diabetes) series comprised eight key trials. AWARD-6 directly compared dulaglutide 1.5 mg to liraglutide 1.8 mg daily in 599 patients and showed non-inferior HbA1c reduction at 26 weeks (both approximately 1.4 percentage points). Non-inferiority to liraglutide, combined with a weekly dosing schedule, was the commercial differentiation point for dulaglutide at launch.

Fasting Glucose and Postprandial Control

Dulaglutide's dominant effect is on fasting plasma glucose, with more modest postprandial action compared to short-acting GLP-1 agents like exenatide twice daily. Retatrutide's postprandial profile has not been fully characterized in published literature, though its GIP component typically enhances meal-stimulated insulin release, suggesting potentially stronger postprandial glucose suppression than pure GLP-1 agonism.

Safety and Tolerability

Gastrointestinal Events

The GI adverse event profile for both drugs follows the class pattern: nausea is most common, typically peaks in the first 4 to 8 weeks of dose escalation, and diminishes with continuation. In AWARD-11, nausea occurred in 19.9 percent of patients on dulaglutide 4.5 mg versus 12.3 percent on 1.5 mg. In the Jastreboff Phase 2 retatrutide trial, nausea was reported in approximately 40 to 47 percent of participants on active drug, with most events graded mild to moderate. Discontinuation due to GI events ran at around 10 to 16 percent in the higher-dose retatrutide cohorts, comparable to rates seen with semaglutide 2.4 mg in STEP-1.

Pancreatitis and Thyroid Risk

Both drugs carry the class-wide boxed warning for medullary thyroid carcinoma (MTC) in rodents and are contraindicated in patients with personal or family history of MTC or Multiple Endocrine Neoplasia type 2. Pancreatitis incidence in GLP-1 trials has not differed significantly from placebo across large CVOTs, but both agents are used cautiously in patients with prior pancreatitis.

Heart Rate

GLP-1 receptor agonism produces a modest increase in resting heart rate, typically 1 to 4 bpm. In REWIND, mean heart rate increased by approximately 1.4 bpm on dulaglutide. The glucagon receptor component of retatrutide could theoretically amplify this effect; in Phase 2, mean heart rate increases were reported but were not associated with adverse cardiac events at 48 weeks.

Injection Site Reactions

Dulaglutide's autoinjector pen, which hides the needle and requires no priming, was associated with low rates of injection-site reactions (below 2 percent in AWARD trials). Retatrutide in Phase 2 was administered via standard prefilled syringe and showed similar low rates of local reactions.

Real-World Evidence: What Exists and What Is Missing

Real-world data for dulaglutide is substantial. Multiple database analyses, including a 2022 cohort study using the US Optum claims database (N<200,000 patients initiating GLP-1 therapy), have confirmed that dulaglutide's HbA1c reduction and cardiovascular event rates in routine clinical care align closely with REWIND and AWARD results. Adherence at 12 months for dulaglutide runs approximately 50 to 60 percent in commercial insurance claims data, which is similar to other once-weekly injectables.

Real-world data for retatrutide is essentially nonexistent. The drug is not commercially approved, so no claims database contains meaningful exposure records. Post-marketing safety registries and observational cohorts will begin accruing only after FDA approval and commercial launch.

Switching Patterns From Dulaglutide in Real-World Datasets

Pharmacoepidemiology studies examining GLP-1 switching show that patients who transition from dulaglutide to higher-efficacy agents (semaglutide or tirzepatide) typically do so because of insufficient weight loss rather than safety concerns. A 2023 analysis of integrated health-system data found that approximately 28 percent of patients initiated on dulaglutide were switched to a different GLP-1 agent within 24 months, with inadequate weight loss documented as the primary reason in 61 percent of switch cases. This pattern suggests that patients currently on Trulicity who require greater than 10 percent weight loss are candidates for a transition conversation once retatrutide achieves approval.

What "Real-World Evidence" Actually Means for Retatrutide Now

Structured expert observation from Phase 2 and Phase 3 open-label extension periods constitutes the closest analog to real-world evidence for retatrutide. The 48-week efficacy data from Jastreboff et al. Reflects a protocol-controlled environment, but the dose-escalation schedule used (starting at 2 mg and titrating every 4 weeks) mirrors how clinicians will likely initiate the drug in practice. Long-term extension data beyond 48 weeks have not been published as of mid-2025.

Dosing, Titration, and Practical Administration

Dulaglutide Dosing

Dulaglutide starts at 0.75 mg once weekly for 4 weeks, then 1.5 mg as the standard maintenance dose. Higher doses (3.0 mg and 4.5 mg) are approved for additional glycemic and weight benefit; dose escalation increments of 1.5 mg every 4 weeks are recommended in the prescribing information. The drug requires refrigeration (2 to 8 degrees Celsius) but may be stored at room temperature (below 30 degrees Celsius) for up to 14 days. Administration uses a single-use autoinjector with a 0.5 mm gauge needle that auto-retracts.

Retatrutide Dosing (Phase 2 Protocol)

The Phase 2 titration scheme started participants at 2 mg once weekly for 4 weeks, then 4 mg for 4 weeks, then either 8 mg or 12 mg as the maintenance dose. This more aggressive escalation schedule, compared to dulaglutide, may explain the higher rates of early GI events. Phase 3 protocols may modify this schedule based on tolerability findings.

Who Should Consider Switching From Trulicity to Retatrutide?

The answer depends heavily on the primary treatment indication. Patients taking dulaglutide for cardiovascular risk reduction in type 2 diabetes should not switch to an unapproved agent. REWIND's 5.4-year cardiovascular outcome data represents a clinical guarantee that retatrutide cannot currently match.

Patients whose primary goal is weight loss exceeding 10 to 15 percent of body weight and who have not achieved that target on dulaglutide are the clearest future candidates for retatrutide, provided they have no contraindications, the drug receives FDA approval, and access is established. Clinicians at HealthRX currently document this subgroup and flag them for reassessment at each quarterly visit.

Patients Who Should Stay on Dulaglutide

Patients with established cardiovascular disease or multiple MACE risk factors, patients in geographic areas where retatrutide formulary access will be delayed, patients who prefer the simplicity of an autoinjector device over a standard prefilled syringe, and patients whose HbA1c is well controlled and weight loss target is modest (3 to 5 percent) are likely better served by continuing dulaglutide.

Patients Who May Benefit From Transition

Adults with class II or class III obesity (BMI 35 or greater) who have not reached a clinically meaningful weight threshold on dulaglutide, and whose cardiovascular risk profile does not uniquely require a drug with a proven CVOT, may be appropriate candidates for retatrutide once it is commercially available. A shared decision-making conversation should document the weight loss goal, baseline BMI, and the patient's understanding that retatrutide's long-term cardiovascular and safety data are still maturing.

Cost, Insurance Coverage, and Access

Dulaglutide's list price in the United States was approximately $880 per month as of early 2025, with widely available manufacturer savings cards reducing out-of-pocket costs for commercially insured patients. Eli Lilly's Trulicity has broad Medicare Part D and commercial formulary coverage, though prior authorization for the weight-loss indication (off-label in Medicare) can be a barrier.

Retatrutide pricing has not been set because the drug is not approved. Based on tirzepatide's launch pricing and the expected premium for a novel triple agonist, market analysts have estimated a list price above $1,000 per month. Formulary placement will depend on FDA label language and Phase 3 weight loss and cardiovascular data.